This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.
To most Nephrologists, Nephronophthisis (NPH) is considered to be a rare autosomal recessive paediatric disease. However, this article by Snoek et al challenges that belief, by examining the prevalence of mutations that cause NPH, in adults with end stage renal disease (ESRD). Read our NephJC summary below and come along to our Twitter Journal Club discussion to find out whether you might consider a diagnosis of NPH, next time you see that patient carrying a label of ‘ESRD, cause unknown’.
